Photo of David Russler-Germain from oncology.wustl.edu
Jun 19, 2024, 13:46
David Russler-Germain: Swapping in BrECADD for PET adapted approaches
David Russler-Germain, Oncology Instructor at Siteman Cancer Center, shared a post by Graham Collins, Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology Centre, shared on X:
“I’m curious whether we (USA) would/should start swapping in BrECADD for PET adapted approaches where we would escalate to escBEACOPP? Maybe?”
Quoting Graham Collins’s post:
“Borchmann – HD21
- 1500 pts, escBEACOPP v BrCADD 1L cHL
- Less Rx-related morbidity (mainly Hb/plt Tx)
- Higher delivery of chemo intensity
- better PFS: 93% at 4year !
- OS no diff
- IPS 3+ did a little worse than 0-2
Incredible results! Practise changing study.”
Source: David Russler-Germain/X and Graham Collins/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19